Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies

Ridaforolimus

(2013)   Drugs in research & development

Targeted therapies in soft tissue sarcomas

(2010) I. Judson   ANNALS OF ONCOLOGY

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information

(2010) E. J. O. Soini et al.   ANNALS OF ONCOLOGY

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas

(2010) Martee L Hensley   CURRENT OPINION IN ONCOLOGY

Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine

(2010) Antonella Perotti et al.   JOURNAL OF CLINICAL ONCOLOGY

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

(2009) C. Sessa et al.   ANNALS OF ONCOLOGY

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

(2009) C. M. Hartford et al.   CLINICAL CANCER RESEARCH

1256 Phase I trial of oral Deforolimus in combination with Bevacizumab in patients with advanced solid tumours

(2009) J. Nemunaitis et al.   EJC SUPPLEMENTS

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

(2009) Stefan Sleijfer et al.   EUROPEAN JOURNAL OF CANCER

Imatinib treatment for gastrointestinal stromal tumour (GIST)

(2009) Lisandro F. Lopes et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma

(2009) Amy M Pick et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY